Table 1.
Modulation of lymphocyte activity after irradiation of tumor tissue.
| Tumor cell | Radiation quality | Dose | Study type | Lymphocyte type | Activity | Reference |
|---|---|---|---|---|---|---|
| Mouse adenocarcinoma | γ-Irradiation (137Cs source) | 20 Gy | In vivo | CTL | ⇑ | (56) |
| 67NR (breast) | γ-Irradiation (60Co source) | 2–6 Gy | In vivo | CTL | ⇑ | (54) |
| A20 (lymphoma) | ||||||
| WiDr (colon) | γ-Irradiation (137Cs source) | 10–20 Gy | In vitro | CTL | ⇑ | (55) |
| Caco-2 (colon) | ||||||
| SW620 (colon) | ||||||
| SW1463 (colon) | ||||||
| HCT116 (colon) | ||||||
| A549 | ||||||
| MelJuSo (melanoma) | γ-Irradiation (137Cs source) | 1–30 Gy | In vitro | CTL | ⇑ | (59) |
| RMA-S lymphoma | Radiation therapy (presumed X-rays) | a | In vivo | NK | ⇑ | (60) |
| B16 melanoma | ||||||
| A549 (lung carcinoma) | X-rays exposure (ClinaciX Linear Accelerator) | 8 Gy | In vitro | NK | ⇑ | (61) |
| NCI-H23 (lung adenocarcinoma) | ||||||
| MDA-MB-231 (breast) | Electron beam exposure (Elekta Synergy linear accelerator) | 8 Gy | In vivo | NK | ⇑ | (62) |
| U87MG (glioblastoma) | ||||||
| A673 (muscle) | ||||||
| PANC-1 (pancreas) | ||||||
| Lewis Lung carcinoma | X-rays exposure (6-MV photon beam, dose rate 6.1 Gy/min) | 12 Gy | In vivo | Treg | ⇑ | (63) |
| CT-26 colon carcinoma | ||||||
| B16 melanoma | γ-Irradiation (137Cs source) | 6–12 Gy | In vivo | Treg | ⇑ | (64) |
| EL-4 lymphoma | ||||||
| PANC-02 (pancreas) | γ-Irradiation (Siemens Gammatron) | 5 Gy × 2 Gy | In vivo | CTL, NK | CTL > NK | (65) |
| LNCaP (prostate) | γ-Irradiation (137Cs source) | 8 Gy | In vivo | CTL | ⇑ | (66) |
| MDA-MB-231 (breast) | ||||||
| H1703 (lung) | Proton ion irradiation (200 MeV, LET 0.5 keV/µm) | 8 Gy | ||||
| JHC7 (chordoma) | ||||||
| Mouse SCCVII (squamous cell carcinoma) | Carbon ion irradiation (290 MeV/n, LET 77 keV/µm) | 10 Gy/minb | In vivo | CTL+ DC | ⇑ | (67) |
⇑ up.
aDose not indicated.
bDuration of irradiation not indicated.
LET, linear energy transfer.